ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2015

Feb 18, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: INOTEK PHARMACEUTICALS CORP (ITEK)
CIK: 0001281895
Period of Report: 2015-02-17

Reporting Person: Pitango Venture Capital Principals Fund IV, L.P. (10% Owner)
Reporting Person: Pitango Venture Capital Fund IV, L.P. (10% Owner)
Reporting Person: Pitango V.C. Fund IV, L.P. (10% Owner)
Reporting Person: Pitango G.C. Capital Holdings Ltd. (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	194642	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series AA Convertible Preferred Stock	$		Common Stock (847424)		Indirect
Convertible Promissory Notes	$		Common Stock (38143)		Indirect

Footnotes

F1: Consists of the following shares of Common Stock: (i) 190,533 shares held directly by Pitango Venture Capital Fund IV L.P. ("Pitango Fund IV") and (ii) 4,109 shares held directly by Pitango Venture Capital Fund Principals IV L.P. ("Pitango Principals IV").

F2: Pitango V.C. Fund IV, L.P. is the General Partner of Pitango Fund IV and Pitango Principals IV, with its own General Partner being Pitango G.P. Capital Holdings Ltd., an Israeli company, owned indirectly by six individuals. These six individuals share voting and dispositive power of the Isuer's shares but none has sole voting or dispositive power of the Issuer's shares.

F3: The Series AA Convertible Preferred Stock ("Series AA Preferred") is convertible at any time at the holder's election and has no expiration date. All shares of Series AA Preferred, including all accrued and unpaid dividends thereon, will be automatically converted on a 4.05783-for-1 basis into shares of Common Stock upon the closing of the Issuer's initial public offering. The number of shares of Common Stock as shown in column 3 is based on a conversion of the following shares of Series AA Preferred: (i) 2,619,795 shares held directly by Pitango Fund IV and (ii) 56,553 shares held directly by Pitango Principals IV, plus accrued and unpaid dividends on each share of Series AA Preferred through the assumed closing date of February 23, 2015.

F4: The outstanding principal amount and all accrued and unpaid interest under the Convertible Promissory Notes will be automatically converted upon the closing of the Issuer's initial public offering into shares of Common Stock at the initial public offering price of $6.00 per share. The Convertible Promissory Notes have no expiration date. The number of shares of Common Stock as shown in column 3 is based on a conversion of the following principal amounts of Convertible Promissory Notes: (i) $220,975.53 held directly by Pitango Fund IV and (ii) $4,771.90 held directly by Pitango Principals IV, plus accrued and unpaid interest through the assumed closing date of February 23, 2015.